TY - JOUR
T1 - New applications for independent activities of daily living in measuring disability in multiple sclerosis
AU - Salter, Amber
AU - Fox, Robert J.
AU - Tyry, Tuula
AU - Cutter, Gary
AU - Marrie, Ruth Ann
N1 - Funding Information:
The Performance Scales have a filed copyright assigned to Deltaquest Foundation, Inc., effective October 1, 2005. US Copyright law governs terms of use. TXu000743629/ 4 April 1996. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The North American Research Committee on Multiple Sclerosis (NARCOMS) is a project of the Consortium of Multiple Sclerosis Centers (CMSC) and is supported by the CMSC and the Foundation of the CMSC.
Funding Information:
IADL scale had a greater ability to discriminate between higher disability levels than RAND-12 domains. The IADL scale may provide a useful and clinically relevant tool to measure disability in progressive MS populations. Activities of daily living multiple sclerosis disability patient-reported outcomes CMSCS edited-state corrected-proof typesetter ts1 The Performance Scales have a filed copyright assigned to Deltaquest Foundation, Inc., effective October 1, 2005. US Copyright law governs terms of use. TXu000743629/ 4 April 1996. Declaration of Conflicting Interests The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: A.S. and T.T. report no disclosures. G. C. serves on data and safety monitoring committees for AMO Pharmaceuticals, BioLineRx, Brainstorm Cell Therapeutics, Galmed Pharmaceuticals, Horizon Pharmaceuticals, Hisun Pharmaceuticals, Merck, Merck/Pfizer, Opko Biologics, Neurim, Novartis, Orphazyme, Sanofi-Aventis, Reata Pharmaceuticals, Receptos/Celgene, Teva pharmaceuticals, the National Heart, Lung, and Blood Institute (NHLBI) (Protocol Review Committee), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (OPRU oversight committee) and on consulting or Advisory Boards for Biogen,Click Therapeutics, Genzyme, Genentech, GW Pharmaceuticals, Klein Buendel Incorporated, MedImmune, MedDay, Novartis, Osmotica Pharmaceuticals, Perception Neurosciences, Recursion Pharmaceuticals, Roche, Somahlution, and TG Therapeutics. R.J.F. receives consultant fees from Actelion, Biogen, Celgene, EMD Serono, Genentech, Immunic, Novartis, and Teva, serves on advisory committees for Actelion, Biogen, Immunic, and Novartis, and receives research grant funding from Novartis. R.A.M. receives research funding from Canadian Institutes of Health Research (CIHR), the National Multiple Sclerosis Society, the Multiple Sclerosis Society of Canada, the Multiple Sclerosis Scientific Research Foundation, Research Manitoba, the Consortium of Multiple Sclerosis Centers, Crohn’s and Colitis Canada, and the Waugh Family Chair in Multiple Sclerosis. Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The North American Research Committee on Multiple Sclerosis (NARCOMS) is a project of the Consortium of Multiple Sclerosis Centers (CMSC) and is supported by the CMSC and the Foundation of the CMSC. ORCID iDs Amber Salter https://orcid.org/0000-0002-1088-110X Robert J Fox https://orcid.org/0000-0002-4263-3717 Ruth Ann Marrie https://orcid.org/0000-0002-1855-5595 Supplemental material Supplemental material for this article is available online.
Publisher Copyright:
© The Author(s), 2020.
PY - 2021/1
Y1 - 2021/1
N2 - Background: Disability outcome measures in multiple sclerosis (MS) focus heavily on ambulation; however, limitations in performing everyday activities encompass another type of disability. Objectives: The aim of this study was to examine the ability of instrumental activities of daily living (IADL) scale to discriminate between different levels of disability and to predict disability progression. Methods: The North American Research Committee on Multiple Sclerosis (NARCOMS) registry fall 2006 semi-annual survey asked participants to complete the RAND-12, Performance Scales, Patient Determined Disease Steps (PDDS), and IADL questionnaires. We modeled the trajectory of disability change, using the PDDS, over 12 years. Analyses used linear and repeated measures regression methods. Results: Of respondents (n = 9931), 9559 (96%) completed the PDDS and IADL scale. Respondents were mostly female (76%), Caucasian (92%), and 52.3 (10.5) years old with moderate disability (median PDDS 4 (early cane)). Mean (SD) IADL total score was 20.5 (3.7). Discriminant ability of the IADL scale was higher than other measures considered at higher levels of disability. Adjusted longitudinal models showed that needing greater assistance on IADLs was independently predictive of trajectories of greater disability change. Conclusion: IADL scale had a greater ability to discriminate between higher disability levels than RAND-12 domains. The IADL scale may provide a useful and clinically relevant tool to measure disability in progressive MS populations.
AB - Background: Disability outcome measures in multiple sclerosis (MS) focus heavily on ambulation; however, limitations in performing everyday activities encompass another type of disability. Objectives: The aim of this study was to examine the ability of instrumental activities of daily living (IADL) scale to discriminate between different levels of disability and to predict disability progression. Methods: The North American Research Committee on Multiple Sclerosis (NARCOMS) registry fall 2006 semi-annual survey asked participants to complete the RAND-12, Performance Scales, Patient Determined Disease Steps (PDDS), and IADL questionnaires. We modeled the trajectory of disability change, using the PDDS, over 12 years. Analyses used linear and repeated measures regression methods. Results: Of respondents (n = 9931), 9559 (96%) completed the PDDS and IADL scale. Respondents were mostly female (76%), Caucasian (92%), and 52.3 (10.5) years old with moderate disability (median PDDS 4 (early cane)). Mean (SD) IADL total score was 20.5 (3.7). Discriminant ability of the IADL scale was higher than other measures considered at higher levels of disability. Adjusted longitudinal models showed that needing greater assistance on IADLs was independently predictive of trajectories of greater disability change. Conclusion: IADL scale had a greater ability to discriminate between higher disability levels than RAND-12 domains. The IADL scale may provide a useful and clinically relevant tool to measure disability in progressive MS populations.
KW - Activities of daily living
KW - disability
KW - multiple sclerosis
KW - patient-reported outcomes
UR - http://www.scopus.com/inward/record.url?scp=85078634451&partnerID=8YFLogxK
U2 - 10.1177/1352458519898591
DO - 10.1177/1352458519898591
M3 - Article
C2 - 31933419
AN - SCOPUS:85078634451
SN - 1352-4585
VL - 27
SP - 97
EP - 106
JO - Multiple Sclerosis Journal
JF - Multiple Sclerosis Journal
IS - 1
ER -